Kristelle Imperio-Lagabon

BACKGROUND: Despite the advances in the multidisciplinary treatment of gastric adenocarcinoma, the overall 5-year survival remains only 33.3% in North America. R0 resection with adequate lymphadenectomy remains the mainstay therapy…

BACKGROUND: Marginal ulceration (MU) following Roux-en-Y gastric bypass (RYGB) is not an uncommon complication and its prevalence ranges from 1-20%…

BACKGROUND: Marginal ulceration (MU) is a significant cause of morbidity after Roux-en-Y gastric bypass (RYGB). Proton pump inhibitor (PPI) therapy is the mainstay of treatment…